Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.33
NVS's Cash-to-Debt is ranked lower than
77% of the 733 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. NVS: 0.33 )
Ranked among companies with meaningful Cash-to-Debt only.
NVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.25 Max: 3.39
Current: 0.33
0.25
3.39
Equity-to-Asset 0.58
NVS's Equity-to-Asset is ranked lower than
55% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. NVS: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
NVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.59 Max: 0.65
Current: 0.58
0.51
0.65
Interest Coverage 11.66
NVS's Interest Coverage is ranked lower than
69% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 88.12 vs. NVS: 11.66 )
Ranked among companies with meaningful Interest Coverage only.
NVS' s Interest Coverage Range Over the Past 10 Years
Min: 11.66  Med: 16.22 Max: 30.91
Current: 11.66
11.66
30.91
Piotroski F-Score: 5
Altman Z-Score: 2.46
Beneish M-Score: -2.67
WACC vs ROIC
7.42%
7.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 16.67
NVS's Operating Margin % is ranked higher than
74% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.19 vs. NVS: 16.67 )
Ranked among companies with meaningful Operating Margin % only.
NVS' s Operating Margin % Range Over the Past 10 Years
Min: 16.67  Med: 20.76 Max: 22.35
Current: 16.67
16.67
22.35
Net Margin % 13.51
NVS's Net Margin % is ranked higher than
75% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NVS: 13.51 )
Ranked among companies with meaningful Net Margin % only.
NVS' s Net Margin % Range Over the Past 10 Years
Min: 13.51  Med: 18.81 Max: 35.29
Current: 13.51
13.51
35.29
ROE % 8.98
NVS's ROE % is ranked higher than
58% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. NVS: 8.98 )
Ranked among companies with meaningful ROE % only.
NVS' s ROE % Range Over the Past 10 Years
Min: 8.95  Med: 14.79 Max: 25.73
Current: 8.98
8.95
25.73
ROA % 5.06
NVS's ROA % is ranked higher than
58% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. NVS: 5.06 )
Ranked among companies with meaningful ROA % only.
NVS' s ROA % Range Over the Past 10 Years
Min: 5.06  Med: 8.59 Max: 16.19
Current: 5.06
5.06
16.19
ROC (Joel Greenblatt) % 49.10
NVS's ROC (Joel Greenblatt) % is ranked higher than
83% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.39 vs. NVS: 49.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 43.78  Med: 59.62 Max: 69.75
Current: 49.1
43.78
69.75
3-Year Revenue Growth Rate 2.90
NVS's 3-Year Revenue Growth Rate is ranked lower than
61% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. NVS: 2.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NVS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.9  Med: 2.5 Max: 12.3
Current: 2.9
-3.9
12.3
3-Year EBITDA Growth Rate -4.80
NVS's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. NVS: -4.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.6  Med: 0.4 Max: 11.6
Current: -4.8
-7.6
11.6
3-Year EPS without NRI Growth Rate -4.80
NVS's 3-Year EPS without NRI Growth Rate is ranked lower than
67% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. NVS: -4.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -7.1  Med: 3.2 Max: 82
Current: -4.8
-7.1
82
GuruFocus has detected 4 Warning Signs with Novartis AG $NVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVS's 10-Y Financials

Financials (Next Earnings Date: 2017-04-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NVS Guru Trades in Q1 2016

Tom Gayner 3,700 sh (New)
John Rogers 13,296 sh (+18.01%)
Sarah Ketterer 316,362 sh (+12.30%)
Jim Simons 3,264,498 sh (+5.61%)
Manning & Napier Advisors, Inc 3,638,373 sh (+3.73%)
Murray Stahl 29,250 sh (+1.74%)
Ken Fisher 6,287,099 sh (+1.59%)
PRIMECAP Management 20,938,858 sh (+0.82%)
First Eagle Investment 12,848 sh (unchged)
Kahn Brothers 27,643 sh (unchged)
Dodge & Cox 45,054,916 sh (-0.12%)
Tweedy Browne 237,664 sh (-1.87%)
Mario Gabelli 6,865 sh (-7.10%)
Mairs and Power 3,780 sh (-7.35%)
Eaton Vance Worldwide Health Sciences Fund 457,700 sh (-48.86%)
» More
Q2 2016

NVS Guru Trades in Q2 2016

John Rogers 14,818 sh (+11.45%)
Ken Fisher 6,363,641 sh (+1.22%)
Sarah Ketterer 319,351 sh (+0.94%)
First Eagle Investment 12,848 sh (unchged)
Kahn Brothers 27,643 sh (unchged)
Tom Gayner 3,700 sh (unchged)
Mairs and Power 3,780 sh (unchged)
Murray Stahl 29,250 sh (unchged)
PRIMECAP Management 20,831,508 sh (-0.51%)
Dodge & Cox 44,366,511 sh (-1.53%)
Tweedy Browne 233,783 sh (-1.63%)
Manning & Napier Advisors, Inc 3,564,657 sh (-2.03%)
Mario Gabelli 6,015 sh (-12.38%)
Jim Simons 2,260,598 sh (-30.75%)
Eaton Vance Worldwide Health Sciences Fund 255,700 sh (-44.13%)
» More
Q3 2016

NVS Guru Trades in Q3 2016

Mairs and Power 6,354 sh (+68.10%)
Jim Simons 2,515,098 sh (+11.26%)
Manning & Napier Advisors, Inc 3,752,105 sh (+5.26%)
Mario Gabelli 6,265 sh (+4.16%)
Sarah Ketterer 321,258 sh (+0.60%)
Kahn Brothers 27,643 sh (unchged)
Tom Gayner 3,700 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
Murray Stahl 29,250 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 255,700 sh (unchged)
PRIMECAP Management 20,557,433 sh (-1.32%)
Dodge & Cox 43,581,886 sh (-1.77%)
Ken Fisher 6,065,150 sh (-4.69%)
Tweedy Browne 220,115 sh (-5.85%)
John Rogers 13,914 sh (-6.10%)
» More
Q4 2016

NVS Guru Trades in Q4 2016

Chris Davis 257,670 sh (New)
Manning & Napier Advisors, Inc 5,554,008 sh (+48.02%)
John Rogers 15,402 sh (+10.69%)
Dodge & Cox 45,718,521 sh (+4.90%)
PRIMECAP Management 21,246,828 sh (+3.35%)
Ken Fisher 6,074,870 sh (+0.16%)
First Eagle Investment 12,848 sh (unchged)
Tom Gayner 3,700 sh (unchged)
Sarah Ketterer 318,018 sh (-1.01%)
Tweedy Browne 216,590 sh (-1.60%)
Kahn Brothers 27,071 sh (-2.07%)
Mairs and Power 6,053 sh (-4.74%)
Mario Gabelli 5,870 sh (-6.30%)
Jim Simons 2,287,000 sh (-9.07%)
Murray Stahl 24,850 sh (-15.04%)
Eaton Vance Worldwide Health Sciences Fund 172,411 sh (-32.57%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:OTCPK:BAYRY » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVSEF.USA,
Novartis AG is engaged in the research, development, manufacturing and marketing of healthcare products and pharmaceuticals.

Novartis develops and manufactures health-care products in four main operating segments: branded drugs, generic pharmaceuticals, eye care products, and consumer products. The company sells its products globally with the U.S. representing close to a third of total sales.

Top Ranked Articles about Novartis AG

Novartis Is Surviving Restructuring leads to promising future business developments
On July 19, the $188 billion Swiss multinational pharmaceutical company delivered its first half fiscal year 2016 results. The company delivered constant currency sales and profit growth of 1% to $24 billion and -2% to $3.8 billion, respectively. Novartis (NYSE:NVS) shares closed -0.62% that day, while the broader S&P 500 index closed -0.14%. Read more...
Does Biotech’s Recent Bounce Have Legs? Examining 3 Big Pharma stocks that dominate the making of cancer-fighting treatments
The beleaguered biotechology sector, which has endured political controversy amid charges of price gouging, is now on an upward trajectory. The Nasdaq Biotechnology Index, after falling 17.46% year to date, has jumped 9.04% over the past month. Read more...

Ratios

vs
industry
vs
history
PE Ratio 26.74
NVS's PE Ratio is ranked higher than
51% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.26 vs. NVS: 26.74 )
Ranked among companies with meaningful PE Ratio only.
NVS' s PE Ratio Range Over the Past 10 Years
Min: 5.7  Med: 15.96 Max: 29.97
Current: 26.74
5.7
29.97
Forward PE Ratio 15.70
NVS's Forward PE Ratio is ranked higher than
56% of the 109 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.08 vs. NVS: 15.70 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 26.74
NVS's PE Ratio without NRI is ranked higher than
51% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.28 vs. NVS: 26.74 )
Ranked among companies with meaningful PE Ratio without NRI only.
NVS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.63  Med: 18.24 Max: 31.15
Current: 26.74
10.63
31.15
Price-to-Owner-Earnings 16.02
NVS's Price-to-Owner-Earnings is ranked higher than
76% of the 302 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.92 vs. NVS: 16.02 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NVS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.18  Med: 15.37 Max: 21.83
Current: 16.02
7.18
21.83
PB Ratio 2.29
NVS's PB Ratio is ranked higher than
61% of the 898 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. NVS: 2.29 )
Ranked among companies with meaningful PB Ratio only.
NVS' s PB Ratio Range Over the Past 10 Years
Min: 1.69  Med: 2.43 Max: 3.95
Current: 2.29
1.69
3.95
PS Ratio 3.62
NVS's PS Ratio is ranked lower than
59% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. NVS: 3.62 )
Ranked among companies with meaningful PS Ratio only.
NVS' s PS Ratio Range Over the Past 10 Years
Min: 1.89  Med: 3.27 Max: 5.01
Current: 3.62
1.89
5.01
Price-to-Free-Cash-Flow 21.79
NVS's Price-to-Free-Cash-Flow is ranked higher than
55% of the 291 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.25 vs. NVS: 21.79 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NVS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.05  Med: 17.11 Max: 26.68
Current: 21.79
7.05
26.68
Price-to-Operating-Cash-Flow 15.54
NVS's Price-to-Operating-Cash-Flow is ranked higher than
58% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.28 vs. NVS: 15.54 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NVS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.77  Med: 13.26 Max: 19.3
Current: 15.54
5.77
19.3
EV-to-EBIT 22.83
NVS's EV-to-EBIT is ranked lower than
60% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.12 vs. NVS: 22.83 )
Ranked among companies with meaningful EV-to-EBIT only.
NVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.6 Max: 26.4
Current: 22.83
8.5
26.4
EV-to-EBITDA 13.19
NVS's EV-to-EBITDA is ranked higher than
60% of the 783 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.99 vs. NVS: 13.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 12.2 Max: 18
Current: 13.19
7.3
18
Shiller PE Ratio 15.11
NVS's Shiller PE Ratio is ranked higher than
89% of the 164 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.73 vs. NVS: 15.11 )
Ranked among companies with meaningful Shiller PE Ratio only.
NVS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.68  Med: 14.7 Max: 21.57
Current: 15.11
9.68
21.57
Current Ratio 1.12
NVS's Current Ratio is ranked lower than
84% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.38 vs. NVS: 1.12 )
Ranked among companies with meaningful Current Ratio only.
NVS' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.4 Max: 2.83
Current: 1.12
0.96
2.83
Quick Ratio 0.84
NVS's Quick Ratio is ranked lower than
82% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. NVS: 0.84 )
Ranked among companies with meaningful Quick Ratio only.
NVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.17 Max: 2.48
Current: 0.84
0.7
2.48
Days Inventory 135.81
NVS's Days Inventory is ranked lower than
61% of the 642 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.23 vs. NVS: 135.81 )
Ranked among companies with meaningful Days Inventory only.
NVS' s Days Inventory Range Over the Past 10 Years
Min: 117.82  Med: 150.76 Max: 183.45
Current: 135.81
117.82
183.45
Days Sales Outstanding 62.61
NVS's Days Sales Outstanding is ranked higher than
62% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.21 vs. NVS: 62.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 63.6 Max: 70.59
Current: 62.61
56.31
70.59
Days Payable 104.96
NVS's Days Payable is ranked higher than
69% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.13 vs. NVS: 104.96 )
Ranked among companies with meaningful Days Payable only.
NVS' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 116.45 Max: 135.35
Current: 104.96
95.93
135.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.66
NVS's Dividend Yield % is ranked higher than
91% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. NVS: 3.66 )
Ranked among companies with meaningful Dividend Yield % only.
NVS' s Dividend Yield % Range Over the Past 10 Years
Min: 1.49  Med: 3.37 Max: 5.11
Current: 3.66
1.49
5.11
Dividend Payout Ratio 0.96
NVS's Dividend Payout Ratio is ranked higher than
69% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. NVS: 0.96 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NVS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.4  Med: 0.64 Max: 0.97
Current: 0.96
0.4
0.97
3-Year Dividend Growth Rate 7.60
NVS's 3-Year Dividend Growth Rate is ranked lower than
54% of the 286 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. NVS: 7.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NVS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -70.6  Med: 7.85 Max: 18.5
Current: 7.6
-70.6
18.5
Forward Dividend Yield % 3.67
NVS's Forward Dividend Yield % is ranked higher than
85% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. NVS: 3.67 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.72
NVS's 5-Year Yield-on-Cost % is ranked higher than
89% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.19 vs. NVS: 4.72 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NVS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.92  Med: 4.34 Max: 6.58
Current: 4.72
1.92
6.58
3-Year Average Share Buyback Ratio 0.70
NVS's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.00 vs. NVS: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: 1.05 Max: 2.4
Current: 0.7
-2.1
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 13.68
NVS's Price-to-Tangible-Book is ranked lower than
88% of the 830 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.52 vs. NVS: 13.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.68  Med: 5.26 Max: 35.21
Current: 13.68
2.68
35.21
Price-to-Intrinsic-Value-Projected-FCF 1.17
NVS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
83% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. NVS: 1.17 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NVS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.76  Med: 1.16 Max: 2.39
Current: 1.17
0.76
2.39
Price-to-Median-PS-Value 1.11
NVS's Price-to-Median-PS-Value is ranked higher than
54% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. NVS: 1.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.72  Med: 1.12 Max: 1.61
Current: 1.11
0.72
1.61
Price-to-Graham-Number 4.04
NVS's Price-to-Graham-Number is ranked lower than
79% of the 546 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.26 vs. NVS: 4.04 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NVS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.24  Med: 2.48 Max: 6.59
Current: 4.04
1.24
6.59
Earnings Yield (Greenblatt) % 4.38
NVS's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 1021 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.62 vs. NVS: 4.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.8  Med: 6.4 Max: 11.8
Current: 4.38
3.8
11.8
Forward Rate of Return (Yacktman) % 4.99
NVS's Forward Rate of Return (Yacktman) % is ranked lower than
60% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.75 vs. NVS: 4.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NVS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1  Med: 13.7 Max: 61.6
Current: 4.99
1
61.6

More Statistics

Revenue (TTM) (Mil) $49,436
EPS (TTM) $ 2.80
Beta0.75
Short Percentage of Float0.19%
52-Week Range $66.93 - 83.58
Shares Outstanding (Mil)2,374.06

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 49,496 53,216 55,361
EPS ($) 4.76 5.28 5.88
EPS without NRI ($) 4.76 5.28 5.88
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.38%
Dividends per Share ($) 2.85 3.03 3.18
» More Articles for NVS

Headlines

Articles On GuruFocus.com
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
Novartis Has Bright Future Feb 01 2017 
2 Top Health Care Dividend Stocks Jan 12 2017 
7 Stocks With Low P/S Ratios Jan 11 2017 
Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
Eli Lily Leaps Over Patent Hurdles Oct 18 2016 
The Pharmaceutical Sector Looks Attractive Oct 12 2016 
Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
Novartis Is Surviving Oct 03 2016 

More From Other Websites
Novartis Makes Plans For Its Cancer-Killing T Cells Mar 29 2017
4:02 pm Novartis AG announces that the FDA has accepted the Biologics License Application filing and... Mar 29 2017
Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe Mar 29 2017
Which Segments Will Drive the Most Growth for Novartis’s Cosentyx? Mar 29 2017
Novartis’s Cosentyx Managed to Achieve Blockbuster Status in 2016 Mar 29 2017
Will Novartis See Rise in Net Profit Margins in 2017? Mar 28 2017
Why Novartis Could Witness Modest Revenue Growth in 2017 Mar 28 2017
What Analysts Recommend for Novartis in 2017 Mar 28 2017
What Do Wall Street Analysts Expect for Novartis? Mar 28 2017
A Look at Novartis’s Financial Guidance and Priorities for 2017 Mar 28 2017
GlaxoSmithKline’s Valuation Compared to Its Peers Mar 28 2017
Bristol-Myers: Maybe a Pfizer Acquisition Could Makes Sense After All? Mar 27 2017
Cambridge-based Ionis spinout Akcea plots $100M IPO Mar 27 2017
Novartis’s Innovative Medicines Segment in 2016 Mar 27 2017
Blog Coverage Novartis Licences its Immunosenescence Drugs to PureTech Health Mar 27 2017
Novartis’s Recent Developments Mar 27 2017
Exploring Novartis’s 2016 Revenue Mar 24 2017
Novartis’s Valuation Compared to Its Peers’ Mar 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)